Financial Performance - The company's operating revenue for Q1 2023 was ¥252,455,900.29, representing a year-on-year increase of 42.58%[5] - The net profit attributable to shareholders for Q1 2023 was ¥36,928,240.19, reflecting a growth of 45.22% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥38,966,750.90, which is an increase of 54.64% year-on-year[5] - Total revenue for Q1 2023 reached ¥252,455,900.29, a significant increase of 42.5% compared to ¥177,067,881.79 in Q1 2022[19] - Operating profit for Q1 2023 was ¥43,644,938.15, up 44.9% from ¥30,115,844.41 in the same period last year[20] - Net profit for Q1 2023 amounted to ¥36,928,240.19, representing a 45.4% increase from ¥25,428,402.43 in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.57, an increase of 9.62% year-on-year[6] - Basic and diluted earnings per share for Q1 2023 were both ¥0.57, compared to ¥0.52 in Q1 2022, marking a 9.6% increase[21] Research and Development - The total R&D investment for Q1 2023 was ¥16,163,087.87, marking a significant increase of 66.05% compared to the previous year[6] - The R&D investment accounted for 6.40% of operating revenue, up by 0.90 percentage points from the previous year[6] - Research and development expenses for Q1 2023 were ¥16,163,087.87, a 66.1% increase from ¥9,733,638.06 in Q1 2022[20] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥2,425,420,936.29, which is a 2.81% increase from the end of the previous year[6] - Total assets increased from CNY 2,359,206,247.92 to CNY 2,425,420,936.29, representing a growth of approximately 2.8%[17] - Total current assets increased from CNY 2,244,601,787.13 to CNY 2,309,998,099.82, reflecting a growth of approximately 2.9%[16] - Current liabilities increased from CNY 249,070,839.56 to CNY 286,230,254.30, showing a rise of about 15%[17] - Non-current liabilities decreased from CNY 31,208,972.64 to CNY 28,539,034.51, reflecting a decline of approximately 8.6%[17] - The company’s total liabilities increased from CNY 280,279,812.20 to CNY 314,769,288.81, indicating a growth of about 12.3%[17] - Total liabilities increased to ¥317,437,607.11 in Q1 2023, compared to ¥283,052,077.86 in Q1 2022, reflecting a growth of 12.1%[18] - The equity attributable to shareholders at the end of Q1 2023 was ¥2,107,983,329.18, reflecting a 1.53% increase compared to the end of the previous year[6] - Total equity rose to ¥2,107,983,329.18 in Q1 2023, up from ¥2,076,154,170.06 in Q1 2022, indicating a growth of 1.5%[18] Cash Flow - The net cash flow from operating activities for Q1 2023 was -¥21,457,616.26, indicating a decrease of 67.02% year-on-year[6] - In Q1 2023, the cash inflow from operating activities totaled $274,832,209.08, compared to $166,550,481.91 in Q1 2022, representing an increase of approximately 64.9%[24] - The cash outflow from operating activities was $296,289,825.34, up from $231,606,316.14 in the previous year, indicating a rise of about 28%[24] - The net cash flow from operating activities was -$21,457,616.26, an improvement from -$65,055,834.23 in Q1 2022[24] - Cash inflow from investment activities was $3,473,049.81, while cash outflow was $10,475,799.19, resulting in a net cash flow of -$7,002,749.38 for investment activities[25] - The cash inflow from financing activities was $194,243.33, compared to $55,099.20 in Q1 2022, showing an increase of approximately 252%[25] - The net cash flow from financing activities was -$3,045,407.93, slightly improved from -$3,633,084.89 in the same quarter last year[25] - The total cash and cash equivalents at the end of Q1 2023 stood at $1,463,790,926.46, down from $1,495,462,681.26 at the beginning of the quarter[25] Market and Future Outlook - The company experienced strong demand in the drug molecular block and scientific reagent segments, contributing to the overall revenue growth[9] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[15] Other Financial Metrics - The company reported a significant increase in accounts receivable from CNY 177,028,268.89 to CNY 219,428,069.98, which is an increase of about 23.9%[16] - Inventory rose from CNY 521,860,490.24 to CNY 574,843,179.86, indicating an increase of about 10.1%[16] - Cash and cash equivalents rose from CNY 1,470,945,899.08 to CNY 1,505,956,232.01, marking an increase of approximately 2.4%[16] - The company reported a total operating cost of ¥203,401,460.75 in Q1 2023, which is an increase of 43.9% from ¥141,216,584.11 in Q1 2022[19] - Other comprehensive income for Q1 2023 showed a loss of ¥14,098,118.88, compared to a loss of ¥80,104.28 in Q1 2022[21] - Employee compensation payments increased to $35,142,187.82 from $33,097,076.01, reflecting a rise of about 6.2%[24] - The company experienced a negative impact of -$165,981.23 from exchange rate fluctuations on cash and cash equivalents[25]
毕得医药(688073) - 2023 Q1 - 季度财报